Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?
Obesity surgery, 2026
Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort
Diabetes, obesity & metabolism, 2026
Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care
AIDS (London, England), 2026
Initiating semaglutide therapy reduces tobacco cigarette smoking intensity among people with HIV
AIDS (London, England), 2026
Endothelial Shear-Stress-Responsive Gene Adenylate Cyclase 4 Suppresses Atherosclerosis by Inhibiting cAMP/PKA-NF-κB Mediated Vascular Inflammation
Arteriosclerosis, thrombosis, and vascular biology, 2026
Pharmacotherapy in obstructive sleep apnoea: a clinical guide
Sleep & breathing = Schlaf & Atmung, 2026;30(4)
Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials
Obesity science & practice, 2026;12(4):e70181
Diagnostic and Management Pitfalls of SGLT2 Inhibitor-Associated Ketoacidosis in the ICU: Lessons Following Cardiac Surgery and GLP-1 Agonist Interaction
Case reports in critical care, 2026;2026:4896065
Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies
Clinics in dermatology, 2026
Incretin-Based Therapies in Obesity-Related Obstructive Sleep Apnea: A Narrative Review of Evidence Tiers and Mechanistic Plausibility
Nature and science of sleep, 2026;18:611573
Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia
Saudi medical journal, 2026;47(9):1516-1523
Venous Congestion in Metabolic Heart Disease: Potential Indirect Role of Dual Incretin Agonists
Cardiovascular & hematological disorders drug targets, 2026
Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes
Pharmaceuticals (Basel, Switzerland), 2026;19(8)
Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice
Endocrinology, diabetes & metabolism;9(5):e70295
Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease
Journal of the American College of Cardiology;87(11):1369-1373
Improvement of Rosacea With Tirzepatide: A Case Report
Journal of drugs in dermatology : JDD;25(8):749-750
Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide
Diabetes/metabolism research and reviews;42(6):e70213
Impact of semaglutide introduction on the use of triptans: an interrupted-time series
The journal of headache and pain, 2026;27(1)
Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey
BMC primary care, 2026;27(1)
Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials
Diabetes, obesity & metabolism, 2026